Kelly CRISPR & Gene Editing Technology ETF (XDNA) Price, Holdings, & News

ETF Overview

The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly.

Key Stats

• Today's Range: $7.38 to $7.38
• 50-Day Range: $7.38 to $7.38
• 52-Week Range: $5.87 to $11.83
• Volume: N/A
• Average Volume: 3,034 shs
• Market Capitalization: $2.21 million
• Assets Under Management: $2.58 million
• Dividend Yield: 0.12%
• Net Expense Ratio: 0.78%
• Aggregate Rating: N/A

XDNA ETF - Frequently Asked Questions

How have XDNA shares performed this year?

Kelly CRISPR & Gene Editing Technology ETF's stock was trading at $7.38 at the beginning of 2025. Since then, XDNA stock has increased by 0.0% and is now trading at $7.38.
View the best growth stocks for 2025 here.

How do I buy shares of Kelly CRISPR & Gene Editing Technology ETF?

Shares of XDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kelly CRISPR & Gene Editing Technology ETF own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kelly CRISPR & Gene Editing Technology ETF investors own include Meta Platforms (META), RTX (RTX), Beam Therapeutics (BEAM), CRISPR Therapeutics (CRSP), Cloudflare (NET), Birkenstock (BIRK) and Baidu (BIDU).

Fund Details

• Issuer: Kelly Strategic Management
• Fund Name: Kelly CRISPR & Gene Editing Technology ETF
• Tax Classification: Regulated Investment Company
• Stock Exchange: NASDAQ
• Current Symbol: NASDAQ:XDNA
• Inception Date: 1/12/2022
• Fund Manager: Dustin Lewellyn, Ernesto Tong, Anand Desai
• Web: N/A
• Phone: N/A

Fund Focus

• Asset Class: Equity
• Benchmark: Strategic CRISPR & Gene Editing Technology Index
• Category: Strategy
• Focus: Theme
• Development Level: Developed Markets
• Region: Global
• Number of Holdings: 2

Fund Statistics

• Assets Under Management: $2.58 million
• Average Daily Volume: $0.00
• Discount/Premium: 0.00%

Administrator, Advisor and Custodian

• Administrator: U.S. Bancorp Fund Services, LLC
• Advisor: Kelly Strategic Management, LLC
• Custodian: U.S. Bank, N.A.
• Distributor: Foreside Fund Services, LLC
• Transfer Agent: U.S. Bancorp Fund Services, LLC
• Trustee: N/A
• Lead Market Maker: Jane Street

Miscellaneous

• Outstanding Shares: 300,000
• Beta: 0.92
• Creation Unit: 25,000
• Creation Fee: $250.00